Investment

Features

Pro Tools for Pro Traders

Uncover the powerful trading features

Pro Features

Pluang Web Trading

Leverage

Built for Investors

Experience investing with simplified features

Pockets

Recurring Buy

USD Yield

Pluang Cuan

Fees

Safety

Academy

Latest for You

Get up-to-date financial news and investing tips & information

Blog

Find various tips & information to become a knowledgeable investor

News and Analysis

Read the latest information about finance and investment

Learn

Become a smarter investor by learning the basics of investing

Glossary

Learn investment terms to understand investing better

Promo & Referral

Discover exclusive opportunities to level up your investments

Investment Clubs (Coming Soon)

Join hands with like-minded investors to grow wealth together

Press (Coming Soon)

Stay updated with our latest news and media coverage

Support

About Us

Contact

Ask

Career

Tax Reporting Guide

Pluang+

Novartis AG (NVS) Stock Price Today

Overview

Financial

Technicals

Analysis

Corporate Action

About

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Technical Indicators

Overall Summary

Bearish (6)

Neutral (9)

Bullish (12)

Performance

NVS ROI

+13.72%

% from 52W High

-3.99%

$116.07

52W Low: $92.27

27 Oct 2023

52W High: $120.89

30 Aug 2024

News

Globe Newswire

Global Buccal Drug Delivery Systems Market Research 2024-2030 Featuring Johnson & Johnson, Pfizer, Sanofi, Novartis, Bayer, Teva Pharmaceuticals, AbbVie, Cipla, and Haleon

Globe Newswire

10d

$12.5 Bn Influenza Vaccine Market to 2032 by Vaccine Type, Technology, Age Group, Route of Administration, and Region

Globe Newswire

10d

Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - Global Forecast 2024-2030

Benzinga

14d

Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts

Globe Newswire

14d

Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions